USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1
- PMID: 40287768
- PMCID: PMC12034148
- DOI: 10.1186/s12935-025-03796-w
USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1
Abstract
Yes-associated protein 1 (YAP1) plays a pivotal role in promoting the progression of hepatocellular carcinoma (HCC). Emerging evidence shows that inducing YAP1 degradation represents a promising strategy. Here, we identified USP24 as a bona fide deubiquitinating enzyme for YAP1. USP24 directly interacts with and deubiquitinates YAP1, thereby stabilizing YAP1 protein levels. Clinically, USP24 was significantly upregulated in HCC tissues and correlated with poor patient prognosis. Depletion of USP24 significantly suppressed the proliferation of HCC cells in vitro, which could be rescued by restoration of YAP1. Consistent with these findings, USP24 knockdown inhibited tumor growth in a xenograft mouse model. Overall, our study reveals that the USP24/YAP1 axis plays a critical role in the malignant progression of HCC, thus providing rationale for potential therapeutic interventions for YAP1-driven HCC.
Keywords: Deubiquitinating enzyme; HCC; Proliferation; USP24; YAP1.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: All animal experiments were approved by The Animal Care & Welfare Committee of Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures






Similar articles
-
USP24 promotes hepatocellular carcinoma tumorigenesis through deubiquitinating and stabilizing TRAF2.Biochem Pharmacol. 2024 Nov;229:116473. doi: 10.1016/j.bcp.2024.116473. Epub 2024 Aug 8. Biochem Pharmacol. 2024. PMID: 39127151
-
Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.Exp Cell Res. 2021 Aug 1;405(1):112646. doi: 10.1016/j.yexcr.2021.112646. Epub 2021 May 21. Exp Cell Res. 2021. PMID: 34029571
-
CDK4/6-mediated phosphorylation of DUB3 promotes YAP1 stability and hepatocellular carcinoma progression.Cell Death Discov. 2025 Apr 30;11(1):212. doi: 10.1038/s41420-025-02493-x. Cell Death Discov. 2025. PMID: 40307228 Free PMC article.
-
Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1.Onco Targets Ther. 2019 Jan 29;12:869-882. doi: 10.2147/OTT.S190061. eCollection 2019. Onco Targets Ther. 2019. PMID: 30774374 Free PMC article.
-
Related cellular signaling and consequent pathophysiological outcomes of ubiquitin specific protease 24.Life Sci. 2024 Apr 1;342:122512. doi: 10.1016/j.lfs.2024.122512. Epub 2024 Feb 22. Life Sci. 2024. PMID: 38395384 Review.
References
-
- Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567. - PMC - PubMed
-
- Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at https://gco.iarc.fr/today. Accessed 08-02-2024.
-
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. - PubMed
-
- Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, Group SIS. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–300. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials